Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]
This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
Phase 3 trial comparing pirtobrutinib (LOXO-305) to ibrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. T…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial update evaluating zanubrutinib in combination with sonrotoclax for relapsed or refractory B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 clinical trial update evaluating nemtabrutinib and lisocabtagene maraleucel for relapsed/refractory chronic lymphocytic leukemia a…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
This observational study investigates cardiac arrhythmias in patients treated with BTK inhibitors or venetoclax in chronic lymphocytic leuke…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 study to evaluate AZD6738 in combination with acalabrutinib in relapsed or refractory chronic lymphocytic leukemia; the trial is act…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers [Phase 2]
This clinical trial update summarizes long-term safety data for pirtobrutinib in participants with previously treated blood cancers from a P…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL [Phase 1, Phase 2]
Phase I/II clinical trial update describing the study of Rapcabtagene Autoleucel in chronic lymphocytic leukemia, small lymphocytic lymphoma…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignan…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 4]
A Phase 4 trial evaluating pirtobrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
An observational prospective study evaluating acalabrutinib for chronic lymphocytic leukemia in real clinical practice in Belarus is ongoing…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 [Phase 1, Phase 2]
Clinical trial evaluating autologous CD19-targeted T cells (CAR-T) for relapsed or chemotherapy-refractory chronic lymphocytic leukemia and …
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) [Phase 1]
Phase 1 clinical trial update for MB-CART19.1 in CD19+ B-cell malignancies sponsored by Miltenyi Biomedicine GmbH. The study includes recurr…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
This entry describes a retrospective study (AQUALIS) to evaluate quality of life in Chronic Lymphocytic Leukemia patients treated with acala…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 clinical trial is evaluating ruxolitinib phosphate to reduce fatigue in patients with chronic lymphocytic leukemia, and the study …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure [Phase 4]
This is a Phase 4 clinical trial comparing acalabrutinib monotherapy to investigator's choice of treatment in patients with chronic lymphocy…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 trial evaluating TriCAR19.20.22 T cells, a CD19/20/22-targeting CAR-T therapy, for relapsed or refractory non-Hodgkin lymphoma, acut…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) [Phase 2]
A Phase 2 clinical trial (DAYBreak CLL-201) evaluating NX-5948 in adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial evaluating acalabrutinib and venetoclax with or without early obinutuzumab for high-risk, recurrent, or refractory ch…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
This clinical trial status update indicates an ongoing natural history study of Monoclonal B-Cell Lymphocytosis, chronic lymphocytic leukemi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia [Phase 3]
This clinical trial update describes a Phase 3 study evaluating whether combining venetoclax with other therapy can enable time-limited trea…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the safety and efficacy of epcoritamab in subjects with relapsed/refractory chronic lymphocytic leukem…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway
Clinical trial update on variation in referral thresholds within the Chronic Lymphocytic Leukemia pathway; the study is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [Phase 1]
A Phase 1 study of JNJ-80948543, a T-cell redirecting trispecific antibody, in Non-Hodgkin lymphoma and chronic lymphocytic leukemia, is cur…